Neurocrine's depression drug is latest asset from Takeda pact to flunk a phase 2 trial - Fierce Biotech

Submitted by Anonymous (not verified) on Tue, 11/11/2025 - 11:25

Neurocrine's depression drug is latest asset from Takeda pact to flunk a phase 2 trial  Fierce Biotech